GS-3242 Injection

DRUG2 trials

Sponsors

Gilead Sciences

Conditions

HIV-1-infection

Phase 2

A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1

RecruitingNCT07645287

Gilead SciencesHIV-1-infection

Start: 2026-06-15End: 2033-04-01Target: 175Updated: 2026-07-10

Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment

Not yet recruitingNCT07708727

Gilead SciencesHIV-1-infection

Start: 2026-07-01End: 2033-04-01Target: 700Updated: 2026-07-16